Last reviewed · How we verify
latanoprost 0.005% QD
At a glance
| Generic name | latanoprost 0.005% QD |
|---|---|
| Sponsor | Inotek Pharmaceuticals Corporation |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- 24-hour Effect of Rocklatan Compared With Latanoprost in Open Angle Glaucoma and Ocular Hypertension Patients (PHASE4)
- Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance (PHASE4)
- Non-inferiority of PRO-067 Ophthalmic Solution vs GAAP Ofteno® in Glaucoma or Ocular Hypertension (PHASE3)
- Double-masked Study of PG324 Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension (PHASE3)
- Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure (PHASE2)
- Safety and Efficacy of T-2345 Compared to Xalatan in Subjects With Primary Open Angle Glaucoma or Ocular Hypertension (PHASE3)
- Study Comparing the Safety and Efficacy of BOL-303259-X to Latanoprost in Subjects With Glaucoma or Ocular Hypertension (PHASE2)
- Multi-center Phase II Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |